Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma

Nature Clinical Practice Oncology volume 5, pages 436–437 (2008)Cite this article

boxed-textEscudier B et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111

Bevacizumab plus interferon α-2a is an acceptable first-line treatment in previously untreated patients with metastatic renal cell carcinoma

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 25–34

    Article  Google Scholar 

  2. Motzer R et al. (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356: 115–124

    Article  CAS  Google Scholar 

  3. Rini B (2008) CALGB Phase III randomized study of interferon alpha- 2b with or without bevacizumab in patients with advanced renal cell carcinoma. Presentation at the ASCO Genitourinary Symposium, San Francisco, February 16, 2008

  4. Rini B et al. (2006) Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma [abstract]. J Clin Oncol 24 (18 Suppl): 4522

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. RA Figlin is the Arthur and Rosalie Kaplan Professor of Medical Oncology and Chairman of the Division of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center and Beckman Research Institute and Associate Director for Clinical Research, City of Hope Comprehensive Cancer Center.

Authors and Affiliations

  1. P Twardowski is Assistant Professor for the Division of Medical Oncology and Experimental Therapeutics at the City of Hope Cancer Center, Duarte, CA, USA.,

    Przemyslaw Twardowski & Robert A Figlin

Authors
  1. Przemyslaw Twardowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A Figlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A Figlin.

Ethics declarations

Competing interests

P Twardowski declared no competing interests. R Figlin is a Consultant and receives grant/research support from the following companies: Novartis, Pfizer and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Twardowski, P., Figlin, R. Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma. Nat Rev Clin Oncol 5, 436–437 (2008). https://doi.org/10.1038/ncponc1162

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1162

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing